GLP1R and metabolic dysfunction-associated steatotic liver disease: In addition, the improvement in NAFLD by GLP-1 correlates with weight loss and other metabolic improvements, and the benefit of GLP-1 agonists for NAFLD may be an indirect effect that acts by improving systemic metabolism, such as improved insulin sensitivity and appetite suppression.